All In Biotech

Drug Trial Radar · NCT07344558

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study of the Safety, Tolerability, and Pharmacokinetics of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Dec 22, 2025

Primary completion

Jun 17, 2026

Study completion Jun 17, 2026

Sponsor

Lead sponsor
Mannkind CorporationIndustry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • MNKD-201(Nintedanib DPI)Drug

    MNKD-201 is a dry powder nintedanib formulation for oral inhalation.

  • PlaceboDrug

    The placebo control in this study is an empty cartridge without any powder.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Cohort 1) Events of BronchospasmTime frame: Up to Day 7
  2. (Cohort 2) Events of BronchospasmTime frame: Up to Day 7
  3. (Cohort 1) Changes in FEV1 (mL) from pre-dose to post-doseTime frame: Up to Day 7
  4. (Cohort 2) Changes in FEV1 (mL) from pre-dose to post-doseTime frame: Up to Day 7
  5. (Cohort 1) Changes in FEV1 / FVC ratio from pre-dose to post-doseTime frame: Up to Day 7
  6. (Cohort 2) Changes in FEV1 / FVC ratio from pre-dose to post-doseTime frame: Up to Day 7
  7. (Cohort 1) Rate of Study Drug DiscontinuationsTime frame: Up to Day 7
  8. (Cohort 2) Rate of Study Drug DiscontinuationsTime frame: Up to Day 7
  9. (Cohort 1) Rate of Study Drug Dose ReductionsTime frame: Up to Day 7
  10. (Cohort 2) Rate of Study Drug Dose ReductionsTime frame: Up to Day 7
  11. (Cohort 1) Rate of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 7
  12. (Cohort 2) Rate of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 7
  13. (Cohort 1) Rate of Treatment Related Adverse Events (TRAEs)Time frame: Up to Day 7
  14. (Cohort 2) Rate of Treatment Related Adverse Events (TRAEs)Time frame: Up to Day 7
  15. (Cohort 1) Rate of Serious Adverse Events (SAEs)Time frame: Up to Day 7
  16. (Cohort 2) Rate of Serious Adverse Events (SAEs)Time frame: Up to Day 7

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • VALDI

    Fresno, California

  • Palmtree Clinical Research

    Palm Springs, California

  • Innova Pharma Research

    Doral, Florida

  • New Life Medical Research

    Hialeah, Florida

  • New Access Research and Medical Services

    Miami, Florida

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • Low Country Research

    Charleston, South Carolina

  • Metroplex Pulmomary & Sleep Center

    McKinney, Texas

  • Pulmonary Medicine Consultants

    McKinney, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.